Jam

Rail Vision (RVSN) received a European patent for its locomotive imaging tech, enhancing sampling of regions of interest (SROI). The system uses train-mounted cameras and processing to capture and analyze visual data. It features a tracking module for rail detection, safety margin definition, and braking distance calculation. By focusing on specific regions, the system achieves higher sampling rates, enabling earlier hazard detection and faster response, improving railway safety and efficiency. This strengthens Rail Vision’s position in the railway safety technology market.

Gaotu Techedu Inc. (GOTU) will release its Q2 2025 earnings on August 26th before U.S. markets open, followed by an earnings call at 8:00 AM ET. Investors are focused on the company’s AI-powered learning solutions and growth strategy. Gaotu’s executives are also expected to address the evolving regulatory environment for edtech in China. A replay of the call will be available on Gaotu’s investor relations website until September 2, 2025. Gaotu aims to revolutionize education with personalized AI-driven solutions for all ages.

CMB.TECH’s merger with Golden Ocean is progressing, with Golden Ocean shareholders voting on approval August 19, 2025. The stock-for-stock merger entails an exchange ratio of 0.95 CMB.TECH shares per Golden Ocean share. Pending shareholder approval and secondary listing on Euronext Oslo Børs, the merger is expected to close around August 20, 2025, initiating trading of new shares on multiple exchanges. The company has received demand letters and faces potential dissenting shareholder actions and legal proceedings, and must complete Golden Ocean’s refinancing.

Novartis announced positive top-line results from Phase III trials (NEPTUNUS-1 and NEPTUNUS-2) evaluating ianalumab (VAY736) in Sjögren’s disease. Both trials met the primary endpoint, showing statistically significant reduction in disease activity. Ianalumab, with its dual mechanism, is poised to potentially be the first targeted treatment for this autoimmune condition. The drug demonstrated a favorable safety profile and will be submitted to global health authorities.

Faraday Future (FFAI) will unveil its strategic “Dual-flywheel, Dual-bridge Eco Strategy” on August 16, 2025. Key updates include expanding into Massachusetts via a partnership with Bos Auto, securing a deposit agreement for 100 FX Super One units. Safety testing of the Super One is underway in Detroit for FMVSS certification. FF has launched a global co-creation campaign for the FX Super One and will showcase both the FF 91 and FX Super One at Monterey Car Week. The company acknowledges addressing VLE industrialization gaps.

Barton Gold (BGDFF) is drilling at its Tarcoola Gold Project’s Tolmer prospect in South Australia, targeting structural controls within the ‘eastern gold zone’. The Tolmer discovery shows promise with grades up to 83.6g/t Au and 17,600g/t Ag. A March 2025 discovery hole had the 5th highest-grade silver intersection globally in H1 2025 (6m @ 4,747 g/t Ag). Recent assays extended high-grade silver horizons and revealed high-grade gold up to ~13g/t Au, in a 1.5km wide mineralized zone.

Western Union will acquire International Money Express, Inc. (Intermex) for $16.00 per share in cash, a deal valued at approximately $500 million. The acquisition aims to strengthen Western Union’s North American retail presence, expand its reach beyond Latin America, and accelerate digital customer acquisition. Western Union anticipates $30 million in annual cost synergies within 24 months. The deal, unanimously approved by both boards of directors, is expected to close in mid-2026, subject to regulatory approvals and Intermex stockholder approval.

RadNet (RDNT) reported record Q2 2025 results, with revenue up 8.4% to $498.2M and Adjusted EBITDA increasing 12.3% to $81.2M. Digital Health segment revenue rose 30.9% to $20.7M. Advanced imaging volumes grew strongly: MRI +9.0%, CT +8.1%, PET/CT +22.4%. Adjusted EPS nearly doubled to $0.31. RadNet raised its 2025 revenue guidance to $1.85-1.90 billion and Adjusted EBITDA to $271-279 million. The company holds $833.2M cash and a low 0.96x leverage ratio.

IO Biotech (IOBT) will release topline results from its Phase 3 trial (IOB-013/KN-D18) of Cylembio, an immune-modulatory cancer vaccine, in combination with KEYTRUDA® for advanced melanoma on August 11, 2025. A conference call and live webcast will detail the data comparing Cylembio plus KEYTRUDA® versus KEYTRUDA® alone as a first-line treatment. The trial focuses on patients with unresectable or metastatic melanoma. A replay will be available on the company website.

China XLX Fertiliser reported strong Q2 2025 results, with revenue up 16.7% QoQ to RMB 6.82 billion and profit surging 103.4% QoQ to RMB 402 million. H1 revenue grew 5% YoY to RMB 12.666 billion, although profit declined 12.8% YoY. The company improved its debt structure and reduced finance expenses. Key operational highlights include increased urea exports and revenue growth in compound fertilizer and methanol segments. Phase II of the Jiangxi Project is scheduled to commence operations in Q3 2025.